<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title xml:lang="ru">Антибиотики и Химиотерапия</journal-title><trans-title-group xml:lang="en"><trans-title>Antibiot Khimioter = Antibiotics and Chemotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0235-2990</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/0235-2990-2024-69-1-2-4-9</article-id><article-id custom-type="edn" pub-id-type="custom">PWLSTC</article-id><article-id custom-type="elpub" pub-id-type="custom">antibiotics-1102</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Скрининговые исследования противомикробной активности пиримидинового соединения  2,2-[6-Бром-2,4-диоксихиназолин-1,3(2Н)диил]бис(N-карбамимидоилацетамид)</article-title><trans-title-group xml:lang="en"><trans-title>Screening Studies of the Antimicrobial Activity of the Pyrimidine Compound 2,2-[6-Bromo-2,4-Dioxoquinazoline-1,3(2H)diyl]bis(N-Carbamimidoylacetamide)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9994-4751</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цибизова</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsibizova</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цибизова Александра Александровна — к. фарм. н., доцент кафедры фармакогнозии, фармацевтической технологии и биотехнологии </p><p>Астрахань</p></bio><bio xml:lang="en"><p>Alexandra A. Tsibizova — Ph. D. in Pharmaceutics, Associate Professor of the Department of Pharmacognosy, Pharmaceutical Technology, and Biotechnology</p><p>Astrakhan</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5417-4477</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Генатуллина</surname><given-names>Г. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Genatullina</surname><given-names>G. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Генатуллина Гузель Наилевна — к. б. н., заместитель руководителя Научно-исследовательского центра, доцент кафедры фармакогнозии, фармацевтической технологии и биотехнологии</p><p>Астрахань</p></bio><bio xml:lang="en"><p>Guzel N. Genatullina — Ph. D. in Biology, Deputy Head of the Research Center, Associate Professor of the Department of Pharmacognosy, Pharmaceutical Technology, and Biotechnology</p><p>Astrakhan</p><p>   </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2998-2864</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ясенявская</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Yasenyavskaya</surname><given-names>A. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ясенявская Анна Леонидовна — к. м. н., доцент, руководитель Научно-исследовательского центра, доцент кафедры фармакогнозии, фармацевтической технологии и биотехнологии</p><p> Бакинская ул., 121. Астраханский ГМУ, г. Астрахань</p></bio><bio xml:lang="en"><p>Anna L. Yasenyavskaya — Ph. D. in Medicine, Associate Professor, Head   of the Research Center, Associate Professor of the Department of Pharmacognosy, Pharmaceutical Technology, and Biotechnology </p><p>121 Bakinskaya st., Astrakhan, State Medical University, Astrakhan</p><p>   </p></bio><email xlink:type="simple">yasen_9@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4721-0959</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Озеров</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ozerov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Озеров Александр Александрович — д. хим. н., профессор, заведующий кафедрой фармацевтической и токсикологической химии</p><p>Волгоград</p></bio><bio xml:lang="en"><p>Alexandr A. Ozerov — D. Sc. in Chemistry, Professor, Head of the Department of Pharmaceutical and Toxicological Chemistry </p><p>Volgograd</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5336-4455</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самотруева</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Samotrueva</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Самотруева Марина Александровна — д. м. н., профессор, заведующая кафедрой фармакогнозии, фармацевтической техно логии и биотехнологии</p><p>Астрахань</p></bio><bio xml:lang="en"><p>Marina A. Samotrueva — D. Sc. in Medicine, Professor, Head of the Department of Pharmacognosy, Pharmaceutical Technology, and Biotechnology</p><p>Astrakhan</p><p>   </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Астраханский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Astrakhan State Medical University of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Волгоградский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical University of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>15</day><month>04</month><year>2024</year></pub-date><volume>69</volume><issue>1-2</issue><fpage>4</fpage><lpage>9</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Цибизова А.А., Генатуллина Г.Н., Ясенявская А.Л., Озеров А.А., Самотруева М.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Цибизова А.А., Генатуллина Г.Н., Ясенявская А.Л., Озеров А.А., Самотруева М.А.</copyright-holder><copyright-holder xml:lang="en">Tsibizova A.A., Genatullina G.N., Yasenyavskaya A.L., Ozerov A.A., Samotrueva M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.antibiotics-chemotherapy.ru/jour/article/view/1102">https://www.antibiotics-chemotherapy.ru/jour/article/view/1102</self-uri><abstract><p>Цель исследования — проведение скрининга противомикробной активности пиримидинового соединения под лабораторным шифром VMA-21-01. Исследование противомикробной активности проводили в отношении: Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumonia, Proteus mirabilis. Противомикробную активность 2,2-[6-Бром-2,4 диоксихиназолин-1,3(2Н)диил]бис(N-карбамимидоилацетамид проводили в условиях in vitro методом серийных разведений и определением его минимальной подавляющей концентрации. Чувствительность микроорганизмов к исследуемому веществу определяли в мясопептонном бульоне (визуальная оценка) с последующим пересевом на мясопептонный агар и подсчётом количества колоний. В качестве контроля использовали пробирки с ДМСО. В качестве препарата сравнения использовали раствор гентамицина 4%. В эксперименте in vitro установлено, что пиримидиновое соединение 2,2-[6-Бром-2,4-диоксихиназолин-1,3(2Н)диил]бис(N-карбамимидоилацетамид) под лабораторным шифром VMA-21-01 обладает бактерицидной активностью в отношении Klebsiella pneumonia, сопоставимой с препаратом сравнения — гентамицином, а также бактериостатической активностью в отношении S. aureus, S. pneumoniae, E. coli, P. mirabilis.  </p><p> </p></abstract><trans-abstract xml:lang="en"><p>The aim of this study was to screen the antimicrobial activity of a pyrimidine compound under the laboratory code VMA-21-01. Antimicrobial activity was studied in relation to: Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumonia, and Proteus mirabilis. The antimicrobial activity of 2,2-[6-Bromo-2,4-dioxoquinazoline- 1,3(2H)diyl]bis(N-carbamimidoylacetamide) was carried out in vitro by serial dilution and determination of its minimum inhibitory concentration. The sensitivity of microorganisms to the test substance was determined in a meat-peptone broth (visual assessment), followed by reinoculation on meat-peptone agar and colony count. DMSO tubes were used as a control. A 4% gentamicin solution was used as a comparison drug. In an in vitro experiment, it was found that the pyrimidine compound 2,2-[6-Bromo-2,4-dioxyquinazoline-1,3(2H)diyl]bis(N-carbamimidoylacetamide) under the laboratory cipher VMA21-01 has bactericidal activity against K. pneumonia comparable to the comparison drug gentamicin, as well as bacteriostatic activity against S. aureus, S. pneumoniae, E. coli, and P. mirabilis. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>пиримидиновые соединения</kwd><kwd>противомикробная активность</kwd><kwd>патогенные и условно-патогенные микроорганизмы</kwd><kwd>бактериостатическая активность</kwd><kwd>метод серийных разведений</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pyrimidine compounds</kwd><kwd>antimicrobial activity</kwd><kwd>pathogenic and opportunistic microorganisms</kwd><kwd>bacteriostatic activity</kwd><kwd>serial dilution method</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Frieri M., Kumar K., Butin A. Antibiotic resistance. J Infect Public Health. 2017; 10 (4): 369–378. doi: 10.1016/j.jiph.2016.08.007.</mixed-citation><mixed-citation xml:lang="en">Frieri M., Kumar K., Butin A. Antibiotic resistance. J Infect Public Health. 2017; 10 (4): 369–378. doi: 10.1016/j.jiph.2016.08.007.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Jamal A. Antibiotics in modern medicine: achievements, obstacles and the future. BULLET: Jurnal Multidisiplin Ilmu. 2023; 2 (2): 548–557.</mixed-citation><mixed-citation xml:lang="en">Jamal A. Antibiotics in modern medicine: achievements, obstacles and the future. BULLET: Jurnal Multidisiplin Ilmu. 2023; 2 (2): 548–557.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Чиряпкин А.С. Обзор производных пиримидина как фармакологически активных соединений. Juvenis scientia. 2022. 8 (5): 16–30. doi: https://doi.org/10.32415/jscientia_2022_8_5_16-30. EDN: CFSWFH</mixed-citation><mixed-citation xml:lang="en">Chiryapkin A.S. Obzor proizvodnykh pirimidina kak farmakologicheski aktivnykh soedinenii. Juvenis scientia. 2022. 8 (5): 16–30. doi: https://doi.org/10.32415/jscientia_2022_8_5_16-30. EDN: CFSWFH (in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zarenezhad E., Farjam M., Iraji A. Synthesis and biological activity of pyrimidine-containing hybrids: emphasis on pharmacological application. Journal of Molecular Structure. 2021; 1230: 129833. doi: 10.1016/j.molstruc.2020.129833.</mixed-citation><mixed-citation xml:lang="en">Zarenezhad E., Farjam M., Iraji A. Synthesis and biological activity of pyrimidine-containing hybrids: emphasis on pharmacological application. 	Journal 	of 	Molecular 	Structure. 	2021; 	1230: 	129833. 	doi: 10.1016/j.molstruc.2020.129833.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Тюренков И.Н., Цибизова А.А., Самотруева М.А., Озеров А.А. Иммунотропные свойства карбонильного производного хиназолина. Астраханский медицинский журнал. 2017; 12 (2): 81–88.</mixed-citation><mixed-citation xml:lang="en">Tyurenkov I.N., Tsibizova A.A., Samotrueva M.A., Ozerov A.A. Immunotropnye svoistva karbonil'nogo proizvodnogo khinazolina. Astrakhanskii Meditsinskii Zhurnal. 2017; 12 (2): 81–88. (in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">ELkanzi N. A. Synthesis and biological activity of some pyrimidine derivatives: a review. Oriental Journal of Chemistry. 2020; 36 (6): 1001. doi: https://doi.org/10.13005/OJC/360602.</mixed-citation><mixed-citation xml:lang="en">ELkanzi N. A. Synthesis and biological activity of some pyrimidine derivatives: a review. Oriental Journal of Chemistry. 2020; 36 (6): 1001. doi: https://doi.org/10.13005/OJC/360602.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed K., Choudhary M. I., Saleem R.S.Z. Heterocyclic pyrimidine derivatives as promising antibacterial agents. Eur J Med Chem. 2023; 259: 115701. doi: 10.1016/j.ejmech.2023.115701.</mixed-citation><mixed-citation xml:lang="en">Ahmed K., Choudhary M. I., Saleem R.S.Z. Heterocyclic pyrimidine derivatives as promising antibacterial agents. Eur J Med Chem. 2023; 259: 115701. doi: 10.1016/j.ejmech.2023.115701.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Andrews B., Komati K., Mohan S. Synthesis and comparison of the antibacterial activity of pyrimidine derivatives. Journal of Chemical Sciences 2017; 129: 335–341. doi: 10.1007/s12039-017-1228-z.</mixed-citation><mixed-citation xml:lang="en">Andrews B., Komati K., Mohan S. Synthesis and comparison of the antibacterial activity of pyrimidine derivatives. Journal of Chemical Sciences 2017; 129: 335–341. doi: 10.1007/s12039-017-1228-z.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Хмидет А.Б.С., Ясенявская А.Л., Цибизова А.А., Тюренков И.Н., Озеров А.А., Самотруева М.А. Оценка противомикробной активности пиримидинового соединения в отношении Klebsiella pneumoniae. Антибиотики и химиотер. 2023; 68 (1–2): 22–26. doi: https://doi.org/10.37489/0235-2990-2023-68-1-2-22-26.</mixed-citation><mixed-citation xml:lang="en">Hmidet A., Yasenyavskaya A.L., Tsibizova A.A., Tyurenkov I.N., Ozerov A.A., Samotrueva M.A. Evaluation of the antimicrobial activity of pyrimidine compound 3-(2-benzyloxy2-oxoethyl)quinazoline-4(3H)-oh in relation to Klebsiella pneumoniae. Antibiot Khimioter = Antibiotics and Chemotherapy. 2023; 68 (1–2): 22–26. doi: https://doi.org/10.37489/0235-2990-2023-68-1-2-22-26. (in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Цибизова А.А., Ясенявская А.Л., Тюренков И.Н., Озеров А.A., Самотруева М.А. Оценка противомикробной активности пиримидинового соединения 2-метил-3-(2-фенил-2-оксоэтил)хиназолин4(3h)-он в отношении Klebsiella pneumoniae в условиях in vivo. Сибирский журнал клинической и экспериментальной медицины. 2023. 38 (1): 175–180. doi: https://doi.org/10.29001/2073-8552-202338-1-175-180</mixed-citation><mixed-citation xml:lang="en">Tsibizova A.A., Yasenyavskaya A.L., Tyurenkov I.N., Ozerov A.A., Samotrueva M.A. Otsenka protivomikrobnoi aktivnosti pirimidinovogo soedineniya 2-metil-3-(2-fenil-2-oksoetil)khinazolin-4(3h)-on v otnoshenii Klebsiella pneumoniae v usloviyakh in vivo. Sibirskii Zhurnal Klinicheskoi i Eksperimental'noi Meditsiny. 2023. 38 (1): 175–180. doi: https://doi.org/10.29001/2073-8552-2023-38-1-175-180 (in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Старикова А.А., Габитова Н.М.К., Цибизова А.А., Озеров А.А., Тюренков И.Н. Башкина О.А. и др. Изучение антимикробной активности новых производных хиназолин-4(3н)-она по отношению к Echerichia coli и Klebsiella pnevmoniae. Астраханский медицинский журнал. 2022; 17 (1): 60–71.</mixed-citation><mixed-citation xml:lang="en">Starikova A.A., Gabitova N.M.K., Tsibizova A.A., Ozerov A.A., Tyurenkov I.N., Bashkina O.A. i dr. Izuchenie antimikrobnoi aktivnosti novykh proizvodnykh khinazolin-4(3n)-ona po otnosheniyu k Echerichia coli i Klebsiella pnevmoniae. Astrakhanskii Meditsinskii Zhurnal. 2022; 17 (1): 60–71. (in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mahasenan K.V., Molina R., Bouley R., Batuecas M.T., Fisher J.F., Hermoso J.A. et al. Conformational dynamics in penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus, allosteric communication network and enablement of catalysis. J Am Chem Soc. 2017; 139 (5): 2102–2110. doi: 10.1021/jacs.6b12565.</mixed-citation><mixed-citation xml:lang="en">Mahasenan K.V., Molina R., Bouley R., Batuecas M.T., Fisher J.F., Hermoso J.A. et al. Conformational dynamics in penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus, allosteric communication network and enablement of catalysis. J Am Chem Soc. 2017; 139 (5): 2102–2110. doi: 10.1021/jacs.6b12565.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mahato A., Shrivastava B., Shanthi N. Synthesis, molecular docking and biological evaluation of substituted quinazolinones as antibacterial agents. Chemical Science Transactions. 2015; 4 (2): 595–603. doi: https://doi.org/10.7598/cst2015.995.</mixed-citation><mixed-citation xml:lang="en">Mahato A., Shrivastava B., Shanthi N. Synthesis, molecular docking and biological evaluation of substituted quinazolinones as antibacterial agents. Chemical Science Transactions. 2015; 4 (2): 595–603. doi: https://doi.org/10.7598/cst2015.995.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Fan Z., Li Yu., Jin Yu., Li H., Lu Yu. J., Yan S. K. et al. Antibacterial activity and mechanism of action of thio phenyl substituted pyrimidine derivative. RSC Adv. 2019; 9 (19): 10739–10744. doi: 10.1039/C9RA01001G.</mixed-citation><mixed-citation xml:lang="en">Fan Z., Li Yu., Jin Yu., Li H., Lu Yu. J., Yan S. K. et al. Antibacterial activity and mechanism of action of thio phenyl substituted pyrimidine derivative. RSC Adv. 2019; 9 (19): 10739–10744. doi: 10.1039/C9RA01001G.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
